This study investigates the effect of TCM characteristic nursing intervention on serum uric acid level and pain symptoms in patients with gout, aiming to provide evidence-based evidence for clinical nursing of gout. Relevant clinical studies on gout patients meeting the criteria were included through computer-based retrieval, and a randomized controlled trial design was adopted to divide the patients into an observation group and a control group. The control group received routine treatment and nursing, while the observation group was given TCM characteristic nursing intervention on the basis of the control group. Outcome indicators such as Serum Uric Acid (SUA) level, pain score (VAS/NRS), inflammatory indicators (CRP, ESR), joint function and quality of life of the two groups were compared before and after intervention. Results A total of 11 clinical studies involving 868 patients were included. After intervention, the serum uric acid level of the observation group was significantly lower than that of the control group [(358.41 ± 48.61) μmol/L vs (412.71 ± 55.21) μmol/L, p < 0.05]; the pain score was significantly reduced, and the VAS score of the observation group at 8 days after intervention was (1.16 ± 0.19) points, lower than (1.38 ± 0.17) points of the control group (p < 0.05); the levels of inflammatory indicators CRP and ESR were significantly improved compared with the control group (p < 0.05); joint swelling degree, joint function classification and quality of life score were all better than those of the control group (p < 0.05); the total effective rate of the observation group (94.12%) was higher than that of the control group (80.39%) (p < 0.05), with a low incidence of adverse reactions and good safety. Conclusion TCM characteristic nursing intervention can effectively reduce the serum uric acid level of gout patients, alleviate pain symptoms, reduce inflammatory response, improve joint function and quality of life. It is simple to operate, safe and effective, and worthy of clinical promotion and application.

Show more

Traditional Chinese Medicine (TCM) has demonstrated multi-target mechanisms and notable clinical efficacy in preventing and treating Precancerous Lesions of Gastric Cancer (PLGC), providing important evidence for optimizing integrated Chinese-Western medical prevention and treatment strategies. Integrating classical TCM theories with modern molecular mechanism studies, including signaling pathway regulation and network pharmacology, as well as clinical trial evidence from randomized controlled trials and cohort studies, existing research has analyzed the therapeutic effects of TCM formulations such as Molodan and Weifuchun, together with acupuncture interventions. TCM attributes PLGC primarily to spleen-stomach deficiency, accompanied by phlegm-stasis entanglement and damp-heat toxin as core pathological characteristics. At the molecular level, active TCM components inhibit abnormal cell proliferation and regulate the apoptosis-proliferation equilibrium through pathways such as EGFR-PI3K-AKT and Hedgehog. Clinically, Molodan achieved an 82.8% reversal rate of gastric mucosal dysplasia after one year treatment, compared with 53.9% in the folic acid control group, while Weifuchun significantly improved gut microbiota composition, notably reducing Parabacteroides abundance. In addition, acupuncture enhances gastric mucosal barrier function via neuro-immunomodulation. Overall, TCM demonstrates holistic and multi-target efficacy in delaying PLGC progression. Future research should leverage nanotechnology and artificial intelligence to deepen mechanistic insights and establish standardized efficacy evaluation frameworks.

Show more

Drug resistance represents a significant factor contributing to poor patient survival and prognosis in lung cancer, frequently mediated by ATP-Binding Cassette (ABC) transporters. This systematic review synthesizes clinical studies, in vitro and in vivo experimental research published between January 2000 and March 2025 in the PubMed and Web of Science databases, alongside analyses of untreated lung cancer cohorts from The Cancer Genome Atlas (TCGA) accessed through the cBioPortal platform. The goal of this review is to evaluate the association between ABC transporter expression, treatment response, drug resistance, and patient survival. Clinical studies have demonstrated considerable heterogeneity in the association between ABC transporter levels in cancer patients and their chemotherapy outcomes. In contrast, non-clinical studies have shown greater consistency in evaluating the roles of certain ABC transporters in drug resistance and tumor progression. Analysis of TCGA data showed that most ABC genes were not intrinsically associated with survival. Overall, our findings indicate that ABC transporters influence lung cancer progression primarily through drug efflux–mediated mechanisms, with limited evidence for intrinsic survival effects in untreated disease. The observed heterogeneity across clinical studies highlights the need for standardized analytical approaches and treatment-specific regimens.

Show more

This study utilizes single-cell RNA sequencing (scRNA-seq) to examine the immune landscape of Pancreatic Ductal Adenocarcinoma (PDA), adjacent healthy tissues, and Peripheral Blood Mononuclear Cells (PBMCs), focusing on CD4+ T cells, CD8+ T cells, and other T cell subsets in tumor and healthy samples. Using Seurat for data processing and Monocle3 for trajectory analysis, identified distinct immune cell populations and disease-related pathways were identified. UMAP and PCA revealed separation between tumor and healthy tissues, suggesting immune evasion in the tumor microenvironment. Monocle3 analysis showed complex branching in tumor-infiltrating T cells, indicative of activation and immunosuppressive states. Differential gene expression highlighted key immune-regulatory pathways upregulated in the tumor, supporting immune modulation within the tumor microenvironment. Despite the small sample size of healthy cells, this study provides valuable insights into immune interactions in PDA and PBMC. Future research should focus on larger cohorts to validate these findings and explore therapeutic strategies targeting immune cells in the tumor microenvironment.

Show more